Form 8-K - Current report

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	August 8, 2024
	Date of Report (Date of earliest event reported)

	NU SKIN ENTERPRISES, INC.
	(Exact name of registrant as specified in its charter)

Delaware		001-12421		87-0565309
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

	75 West Center Street Provo, Utah 84601
	(Address of principal executive offices and zip code)

	[phone]
	(Registrant’s telephone number, including area code)

	N/A
	(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, $.001 par value	NUS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

---

Item 2.02

Results of Operations and Financial Condition.

On August 8, 2024, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three- and six-month periods ended June 30, 2024, and certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.

The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

99.1	Nu Skin Enterprises’ press release dated August 8, 2024, regarding financial results for the three- and six-month periods ended June 30, 2024.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	NU SKIN ENTERPRISES, INC.
	(Registrant)
	/s/ James D. Thomas
	James D. Thomas
	Chief Financial Officer
Date:  August 8, 2024

 

---

---

Exhibit 99.1

FOR IMMEDIATE RELEASE

Nu Skin Enterprises Reports Second Quarter Results

PROVO, Utah — Aug. 8, 2024 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced second quarter results in line with top-line guidance.

 

Executive Summary

Q2 2024 vs. Prior-year Quarter

 

Revenue			$439.1 million; (12.2)% •          (4.2)% FX impact or $(21.0) million •          Rhyz revenue $67.8 million; 32.3%
Earnings Per Share (EPS)			$(2.38) or $0.21 excluding restructuring and impairment charges, compared to $0.54
Customers			893,514; (14)%
Paid Affiliates			155,486; (17)% or (9)% excluding an adjustment to eligibility requirements
Sales Leaders			38,592; (16)%

 

“We are pleased with our progress as we perform to plan on our transformational efforts, and we are on track as evidenced by our second quarter results,” said Ryan Napierski, Nu Skin president and CEO. “Our revenue was in-line with our expectations despite a 4 percent FX headwind, while adjusted earnings per share slightly exceeded our projections due to heightened operational discipline, excluding our restructuring and impairment charges. As our core Nu Skin business continues to navigate the macro-economic environment, we were encouraged by sequential gains in several of our markets including the U.S. and most of Southeast Asia/Pacific. Additionally, our Rhyz business grew 32 percent versus the prior-year quarter led by strong performances in our Mavely affiliate platform and manufacturing companies.

 

“We are intensifying our transformation efforts to become a leading integrated beauty, wellness and lifestyle ecosystem by building synergistic value between our Nu Skin core and Rhyz. In late July, we held our first Western market, in-person affiliate event in over five years with a similar event for Eastern markets coming in September. At the event, we were able to drive energy and alignment among our leaders as we previewed our MYND360 cognitive health division and promoted new activation efforts to grow our salesforce. We also announced plans for a Nu Skin/Mavely app, with Mavely’s more than 1,200 brands and 70,000 everyday influencers, for our Nu Skin affiliates, anticipated for second-half introduction in the U.S.

 

---

Nu Skin Enterprises Reports Second Quarter 2024 Financial Results

page 2

“We are enhancing our developing market strategy including a revised business model, targeted product offering and streamlined operating infrastructure beginning with Latin America and parts of Southeast Asia in the second half. In addition, we are intensifying our plans to enter India with a proprietary business model that will be a catalyst for expansion into other emerging markets. We are also exploring integrated brand building initiatives, including digital marketing and third-party marketplaces, as we strive to be wherever our customers seek to find us.”

 

Q2 2024 Year-over-year Operating Results

 

Revenue			$439.1 million compared to $500.3 million •          (4.2)% FX impact or $(21.0) million •          Rhyz revenue $67.8 million; +32.3%
Gross Margin			70.0% compared to 72.9% •          Nu Skin business was 76.1% compared to 77.2%
Selling Expenses			37.7% compared to 37.0% •          Nu Skin business was 42.2% compared to 40.2%
G&A Expenses			26.9% compared to 27.4%
Operating Margin			(28.6)% or 5.4% excluding restructuring and impairment charges compared to 8.5%
Interest Expense			$6.7 million compared to $5.8 million
Other Income/(Expense)			$0.6 million compared to $0.4 million
Income Tax Rate			10.2% or 41.4% excluding restructuring and impairment charges compared to 27.5%
EPS			$(2.38) or $0.21 excluding restructuring and impairment charges compared to $0.54

Stockholder Value

 

Dividend Payments			$3.0 million
Stock Repurchases			$0.0 million •          $162.4 million remaining in authorization

---

Nu Skin Enterprises Reports Second Quarter 2024 Financial Results

page 3

Q3 and Full-year 2024 Outlook

 

Q3 2024 Revenue			$430 to $465 million; (14)% to (7)% •          Approximately (4) to (3)% FX impact
Q3 2024 EPS			$0.08 to $0.18 or $0.15 to $0.25 non-GAAP
2024 Revenue			$1.73 to $1.81 billion; (12)% to (8)% •          Approximately (4) to (3)% FX impact
2024 EPS			$(2.01) to $(1.81) or $0.75 to $0.95 non-GAAP

“As we continue to refine our operating model during our transformation, we remain diligent in pursuing cost saving initiatives going forward, including additional product portfolio optimization along with expense management,” said James D. Thomas, chief financial officer.  “We remain on track with our cost efficiency program as reflected by our reductions in G&A expense, helping to protect profitability despite revenue pressures. During the quarter, we generated $51.2 million in cash from operations, reduced inventory levels and paid down debt to strengthen our balance sheet. We also performed an impairment analysis and recorded a $141 million non-cash charge for impairment of goodwill and other intangibles as a result of the decline in stock price and current market conditions.

 

“Given that we have performed in-line with expectations for the first half of the year while also considering the increasing FX headwind, we believe it prudent to narrow our annual revenue guidance range. We are now projecting 2024 revenue in the $1.73 to $1.81 billion range, with earnings of $(2.01) to $(1.81) or $0.75 to $0.95 excluding restructuring and impairment charges. Our Q3 guidance assumes continued sequential improvement with projected revenue of $430 to $465 million and earnings per share of $0.08 to $0.18 or $0.15 to $0.25 excluding restructuring and impairment charges.”

 

Conference Call

 

The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through Aug. 22, 2024.

 

---

Nu Skin Enterprises Reports Second Quarter 2024 Financial Results

page 4

About Nu Skin Enterprises Inc.

 

The Nu Skin Enterprises Inc. (NYSE: NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company’s products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

 

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the macro environment and the company’s performance, growth and growth opportunities, strategies, sales force, shareholder value, product previews and launches, product portfolio optimization, transformation, evolution, operational and financial initiatives, digital tools and initiatives, new market expansion, and plans for developing and emerging markets; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, future dividends, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “anticipate,” “become,” “”plan,” accelerate,” “project,” “continue,” “outlook,” “guidance,” “improve,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

 

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

 

•

any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;

•

risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;

•

economic conditions and events globally;

•

competitive pressures in the company’s markets;

•

risk that epidemics, including COVID-19 and related disruptions, or other crises could negatively impact our business;

•

adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;

•

political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;

 

---

Nu Skin Enterprises Reports Second Quarter 2024 Financial Results

page 5

•

uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;

•

risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;

•

uncertainties regarding the future financial performance of the businesses the company has acquired;

•

risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;

•

regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements; and

•

the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets outside of the United States, and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets.

 

The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

 

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

 

Earnings per share, operating margin and income tax rate, each excluding restructuring and impairment charges, also are non-GAAP financial measures. Restructuring and impairment charges are not part of the ongoing operations of our underlying business. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these charges facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, operating margin and income tax rate calculated under GAAP, below.

 

---

Nu Skin Enterprises Reports Second Quarter 2024 Financial Results

page 6

The following table sets forth revenue for the three-month periods ended June 30, 2024, and 2023 for each of our reportable segments (U.S. dollars in thousands):

		Three Months Ended June 30,												Constant- Currency
		2024				2023				Change				Change
Nu Skin
Americas		$	84,935			$	107,641				(21.1	)%			(15.1	)%
Mainland China			64,710				88,362				(26.8	)%			(24.5	)%
Southeast Asia/Pacific			60,341				63,764				(5.4	)%			(0.5	)%
Japan			42,587				50,862				(16.3	)%			(4.9	)%
South Korea			44,119				53,686				(17.8	)%			(14.3	)%
Europe & Africa			40,714				46,968				(13.3	)%			(12.3	)%
Hong Kong/Taiwan			33,846				37,108				(8.8	)%			(5.5	)%
Nu Skin other			(4	)			597				(100.7	)%			(100.8	)%
Total Nu Skin			371,248				448,988				(17.3	)%			(12.6	)%
Rhyz Investments
Manufacturing			51,473				45,551				13.0	%			13.0	%
Rhyz other			16,360				5,718				186.1	%			186.1	%
Total Rhyz Investments			67,833				51,269				32.3	%			32.3	%
Total		$	439,081			$	500,257				(12.2	)%			(8.0	)%

The following table sets forth revenue for the six-month periods ended June 30, 2024, and 2023 for each of our reportable segments (U.S. dollars in thousands):

		Six Months Ended June 30,												Constant- Currency
		2024				2023				Change				Change
Nu Skin
Americas		$	159,966			$	208,798				(23.4	)%			(17.5	)%
Mainland China			125,777				156,338				(19.5	)%			(16.5	)%
Southeast Asia/Pacific			120,406				131,574				(8.5	)%			(4.4	)%
Japan			86,823				103,468				(16.1	)%			(5.3	)%
South Korea			85,082				124,010				(31.4	)%			(28.5	)%
Europe & Africa			82,987				94,412				(12.1	)%			(12.1	)%
Hong Kong/Taiwan			64,312				71,656				(10.2	)%			(7.6	)%
Nu Skin other			668				482				38.6	%			38.6	%
Total Nu Skin			726,021				890,738				(18.5	)%			(14.1	)%
Rhyz Investments
Manufacturing			101,775				81,318				25.2	%			25.2	%
Rhyz other			28,591				9,663				195.9	%			195.9	%
Total Rhyz Investments			130,366				90,981				43.3	%			43.3	%
Total		$	856,387			$	981,719				(12.8	)%			(8.8	)%

---

Nu Skin Enterprises Reports Second Quarter 2024 Financial Results

page 7

The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended June 30, 2024, and 2023:

		Three Months Ended June 30,
		2024				2023				Change
Customers
Americas			226,626				263,138				(14	)%
Mainland China			179,021				214,907				(17	)%
Southeast Asia/Pacific			88,662				106,283				(17	)%
Japan			109,357				112,484				(3	)%
South Korea			99,358				112,019				(11	)%
Europe & Africa			143,336				177,472				(19	)%
Hong Kong/Taiwan			47,154				54,815				(14	)%
Total Customers			893,514				1,041,118				(14	)%

Paid Affiliates
Americas			29,531				36,048				(18	)%
Mainland China			24,404				28,825				(15	)%
Southeast Asia/Pacific(1)			29,701				32,769				(9	)%
Japan(1)			21,575				36,765				(41	)%
South Korea			22,116				23,012				(4	)%
Europe & Africa			17,402				19,906				(13	)%
Hong Kong/Taiwan			10,757				10,327				4	%
Total Paid Affiliates			155,486				187,652				(17	)%

Sales Leaders
Americas			6,070				7,872				(23	)%
Mainland China			10,266				13,777				(25	)%
Southeast Asia/Pacific			5,601				5,814				(4	)%
Japan			6,116				5,853				4	%
South Korea			4,689				5,784				(19	)%
Europe & Africa			3,432				4,105				(16	)%
Hong Kong/Taiwan			2,418				2,602				(7	)%
Total Sales Leaders			38,592				45,807				(16	)%

(1)  The June 30, 2024, number is affected by a change in eligibility requirements for receiving certain rewards within our compensation structure. We plan to implement these changes in additional segments over the next several quarters.

●

“Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.

●

“Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.

●

“Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.

---

Nu Skin Enterprises Reports Second Quarter 2024 Financial Results

page 8

NU SKIN ENTERPRISES, INC.

Consolidated Statements of Income (Unaudited)

(U.S. dollars in thousands, except per share amounts)

		Three Months Ended June 30,								Six Months Ended June 30,
		2024				2023				2024				2023
Revenue		$	439,081			$	500,257			$	856,387			$	981,719
Cost of sales			131,904				135,542				255,146				269,130
Gross profit			307,177				364,715				601,241				712,589
Operating expenses:
Selling expenses			165,463				185,165				319,005				373,289
General and administrative expenses			117,921				137,044				242,487				270,943
Restructuring and impairment expenses			149,350				—				156,484				9,787
Total operating expenses			432,734				322,209				717,976				654,019
Operating income (loss)			(125,557	)			42,506				(116,735	)			58,570
Interest expense			6,720				5,769				14,045				10,657
Other expense, net			629				376				233				3,788
Income (loss) before provision for income taxes			(131,648	)			37,113				(130,547	)			51,701
Provision (benefit) for income taxes			(13,390	)			10,221				(11,756	)			13,433
Net income (loss)		$	(118,258	)		$	26,892			$	(118,791	)		$	38,268
Net income (loss) per share:
Basic		$	(2.38	)		$	0.54			$	(2.39	)		$	0.77
Diluted		$	(2.38	)		$	0.54			$	(2.39	)		$	0.76
Weighted-average common shares outstanding (000s):
Basic			49,688				49,931				49,613				49,789
Diluted			49,688				50,161				49,613				50,098

---

Nu Skin Enterprises Reports Second Quarter 2024 Financial Results

page 9

NU SKIN ENTERPRISES, INC.

Consolidated Balance Sheets (Unaudited)

(U.S. dollars in thousands)

		June 30, 2024				December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents		$	224,250			$	256,057
Current investments			8,671				11,759
Accounts receivable, net			71,554				72,879
Inventories, net			243,994				279,978
Prepaid expenses and other			105,937				81,198
Total current assets			654,406				701,871
Property and equipment, net			411,918				432,965
Operating lease right-of-use assets			88,071				90,107
Goodwill			99,885				230,768
Other intangible assets, net			88,464				105,309
Other assets			243,228				245,443
Total assets		$	1,585,972			$	1,806,463
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	36,305			$	43,505
Accrued expenses			242,288				260,366
Current portion of long-term debt			30,000				25,000
Total current liabilities			308,593				328,871
Operating lease liabilities			70,318				70,943
Long-term debt			428,327				478,040
Other liabilities			92,570				106,641
Total liabilities			899,808				984,495
Commitments and contingencies
Stockholders’ equity:
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued			91				91
Additional paid-in capital			621,440				621,853
Treasury stock, at cost – 40.9 million and 41.1 million shares			(1,564,090	)			(1,570,440	)
Accumulated other comprehensive loss			(116,995	)			(100,006	)
Retained earnings			1,745,718				1,870,470
Total stockholders' equity			686,164				821,968
Total liabilities and stockholders’ equity		$	1,585,972			$	1,806,463

---

Nu Skin Enterprises Reports Second Quarter 2024 Financial Results

page 10

NU SKIN ENTERPRISES, INC.

Reconciliation of Operating Margin Excluding Impact of Restructuring and Impairment to GAAP Operating Margin

(in thousands, except for per share amounts)

		Three months ended June 30,								Six months ended June 30,
		2024				2023				2024				2023
Operating Income		$	(125,557	)		$	42,506			$	(116,735	)		$	58,570
Impact of restructuring and impairment:
Restructuring and impairment			149,350				-				156,484				9,787
Adjusted operating income		$	23,793			$	42,506			$	39,749			$	68,357
Operating margin			(28.6	)%			8.5	%			(13.6	)%			6.0	%
Operating margin, excluding restructuring impact			5.4	%			8.5	%			4.6	%			7.0	%
Revenue		$	439,081			$	500,257			$	856,387			$	981,719

NU SKIN ENTERPRISES, INC.

Reconciliation of Effective Tax Rate Excluding Impact of Restructuring and Impairment to GAAP Effective Tax Rate

(in thousands, except for per share amounts)

		Three months ended June 30,								Six months ended June 30,
		2024				2023				2024				2023
Provision (benefit) for income taxes		$	(13,390	)		$	10,221			$	(11,756	)		$	13,433
Impact of restructuring and impairment on provision for income taxes			20,715				-				23,071				2,593
Provision for income taxes, excluding impact of restructuring and impairment		$	7,325			$	10,221			$	11,315			$	16,026
Income before provision for income taxes			(131,648	)			37,113				(130,547	)			51,701
Impact of restructuring and impairment expense:
Restructuring and impairment			149,350				-				156,484				9,787
Income before provision for income taxes, excluding impact of restructuring and impairment		$	17,702			$	37,113			$	25,937			$	61,488
Effective tax rate			10.2	%			27.5	%			9.0	%			26.0	%
Effective tax rate, excluding restructuring and impairment impact			41.4	%			27.5	%			43.6	%			26.1	%

---

Nu Skin Enterprises Reports Second Quarter 2024 Financial Results

page 11

NU SKIN ENTERPRISES, INC.

Reconciliation of Earnings Per Share Excluding Impact of Restructuring and Impairment to GAAP Earnings Per Share

(in thousands, except for per share amounts)

		Three months ended June 30,								Six months ended June 30,
		2024				2023				2024				2023
Net income		$	(118,258	)		$	26,892			$	(118,791	)		$	38,268
Impact of restructuring and impairment expense:
Restructuring and impairment			149,350				-				156,484				9,787
Tax impact			(20,715	)			-				(23,071	)			(2,593	)
Adjusted net income		$	10,377			$	26,892			$	14,622			$	45,462
Diluted earnings per share		$	(2.38	)		$	0.54			$	(2.39	)		$	0.76
Diluted earnings per share, excluding restructuring impact		$	0.21			$	0.54			$	0.29			$	0.91
Weighted-average common shares outstanding (000)			49,688				50,161				49,613				50,098

NU SKIN ENTERPRISES, INC.

Reconciliation of Earnings Per Share Excluding Impact of Restructuring and Impairment to GAAP Earnings Per Share

		Three months ended September 30, 2024								Year ended December 31, 2024
		Low end				High end				Low end				High end
Earnings Per Share		$	0.08			$	0.18			$	(2.01	)		$	(1.81	)
Impact of restructuring and impairment expense:
Restructuring and impairment			0.10				0.10				3.25				3.25
Tax impact			(0.03	)			(0.03	)			(0.50	)			(0.50	)
Adjusted EPS		$	0.15			$	0.25			$	0.75			$	0.95

# # #

CONTACTS:

Media: [e-mail], [phone]

Investors: [e-mail], [phone]

 

---

Document and Entity Information	Aug. 08, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Aug. 08, 2024
Entity File Number	001-12421
Entity Registrant Name	NU SKIN ENTERPRISES, INC.
Entity Central Index Key	0001021561
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0565309
Entity Address, Address Line One	75 West Center Street
Entity Address, City or Town	Provo
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84601
City Area Code	801
Local Phone Number	345-1000
Title of 12(b) Security	Class A Common Stock, $.001 par value
Trading Symbol	NUS
Security Exchange Name	NYSE
Entity Emerging Growth Company	false
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false

---